Mitochondria as a pharmacological target: Magnum overview

IUBMB Life

Volumn 65, Issue 3, 2013, Pages 273-281

  Olszewska, Anna ^a   Szewczyk, Adam ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

biosensor; mitochondria; mitochondrial drug induced toxicity; mitochondrial drugs

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 2,4 DINITROPHENOL; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTIMYCIN A1; ATRACTYLOSIDE; AUROVERTIN; BEDAQUILINE; BETULIC ACID; BONGKREKIC ACID; CROMAKALIM; CYANIDE; CYCLOSPORIN A; DIAZOXIDE; DIMEBON; GLIBENCLAMIDE; IDEBENONE; METFORMIN; MINOCYCLINE; MYXOTHIAZOL; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NICORANDIL; NIGERICIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMYCIN; PINACIDIL; RESVERATROL; ROTENONE; THIOCTIC ACID; UNINDEXED DRUG; VALINOMYCIN;

AFRICAN TRYPANOSOMIASIS; ASCARIS SUUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SAFETY; ELECTRON TRANSPORT; ENDOCYTOSIS; EUKARYOTIC CELL; HAEMONCHUS CONTORTUS; HUMAN; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; RESPIRATORY CHAIN; REVIEW; STREPTOMYCETACEAE;

ALZHEIMER DISEASE; ANTIOXIDANTS; CELL DEATH; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT; ENZYME INHIBITORS; HUMANS; IONOPHORES; MITOCHONDRIA; MUTATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; POTASSIUM CHANNEL BLOCKERS; UNCOUPLING AGENTS;

EID: 84874484945     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1147     Document Type: Review

References (67)

1. Altmann, R., (1890) Die Elementarorganismen Und Ihre Beziehungen Zu Den Zellen. p. 145, Veit and comp., Leipzig, Germany.
2. Ernster, L., and, Schatz, G., (1981) Mitochondria: a historical review. J. Cell Biol. 91, 227-255.
3. Scheffer, I. E., (2000) A century of mitochondrial research: achievements and perspectives. Mitochondrion 1, 3-31.
4. Marchetti, P., Susin, S. A., Decaudin, D., Gamen, S., Castedo, M., et al. (1996) Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. 56, 2033-2038.
5. Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and, Wang, X., (1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86, 147-157.
6. Wallace, K., B., (2008) Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 29, 361-366.
7. Toogood, P. L., (2008) Mitochondrial drugs. Curr. Opin. Chem. Biol. 12, 457-463.
8. Scatena, R., Bottoni, P., Botta, G., Martorana, G. E., and, Giardina, B., (2007) The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am. J. Physiol. Cell Physiol. 293, C12-C21.
9. Cohen, B. H., (2010) Pharmacologic effects on mitochondrial function. Dev. Disabil. Res. Rev. 16, 189-199.
10. Finsterer, J., (2009) Treatment of mitochondrial disorders. Eur. J. Paediatr. Neurol. 14, 29-44.
11. Finsterer, J., and, Segall, L., (2010) Drugs interfering with mitochondrial disorders. Drug Chem. Toxicol. 33, 138-151.
12. Neustadt, J., and, Pieczenik, S. R., (2008) Medication-induced mitochondrial damage and disease. Mol. Nutr. Food Res. 52, 780-788.
13. Barbosa, I. A., Machado, N. G., Skildum, A. J., Scott, P. M., and, Oliveira, P. J., (2012) Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies. Biochim. Biophys. Acta. 1826, 238-254.
14. Kita, K., Miyadera, H., Saruta, F., and, Miyoshi, H., (2001) Parasite Mitochondria as a Target for Chemotherapy. J. Health Sci. 47, 219-239.
15. Lewis, W., (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res. 58, 189-197.
16. Short, T. G., and, Young, Y., (2003) Toxicity of intravenous anaesthetics. Best Pract. Res. Clin. Anaesthesiol. 17, 77-89.
17. Szewczyk, A., and, Wojtczak, L., (2002) Mitochondria as a pharmacological target. Pharmacol. Rev. 54, 101-127.
18. Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and, Fromenty, B., (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 54, 773-794.
19. Apostolova, N., Blas-García, A., and, Esplugues, J. V., (2011) Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol. Sci. 32, 715-725.
20. Pereira, C. V., Moreira, A. C., Pereira, S. P., Machado, N. G., Carvalho, F. S., et al. (2009) Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr. Drug Saf. 4, 34-54.
21. Dykens, J. A., and, Will, Y., (2007) The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today. 12, 777-785.
22. Moreira, A. C., Machado, N. G., Bernardo, T. C., Sardao, S. A., and, Oliveira, P. J., (2011) Mitochondria as a biosensor for drug-induced toxicity-is it really relevant? In Biosensors for Health, Environment and Biosecurity (, Andrea Serra, P., ed.). InTech.
23. Javadov, S., Hunter, J. C., Barreto-Torres, G., and, Parodi-Rullan, R., (2011) Targeting the mitochondrial permeability transition: cardiac ischemia-reperfusion versus carcinogenesis. Cell Physiol. Biochem. 27, 179-190.
24. Szewczyk, A., Jarmuszkiewicz, W., and, Kunz, W. S., (2009) Mitochondrial potassium channels. IUBMB Life. 61, 134-143.
25. Facundo, H. T., Fornazari, M., and, Kowaltowski, A. J., (2006) Tissue protection mediated by mitochondrial K+ channels. Biochim. Biophys. Acta. 1762, 202-212.
26. Busija, D. W., Lacza, Z., Rajapakse, N., Shimizu, K., Kis, B., et al. (2004) Targeting mitochondrial ATP-sensitive potassium channels-a novel approach to neuroprotection. Brain Res. Brain Res. Rev. 46, 282-294.
27. Gruber, J., Fong, S., Chen, C., Yoong, S., Pastorin, G., et al. (2012) Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol. Adv. 27. doi: 10.1016/j.biotechadv.
28. Sheu, S. S., Nauduri, D., and, Anders, M. W., (2006) Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta. 1762, 256-265.
29. Mancuso, M., Orsucci, D., Volpi, L., Calsolaro, V., and, Siciliano, G., (2010) Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr. Drug Targets 11, 111-121.
30. Lee, J., Boo, J. H., and, Ryu, H., (2009) The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start? Adv. Drug Deliv. Rev. 61, 1316-1323.
31. Swerdlow, R. H., (2009) Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals (Basel) 2, 150-167.
32. Hisatomi, T., Ishibashi, T., Miller, J. W., and, Kroemer, G., (2009) Pharmacological inhibition of mitochondrial membrane permeabilization for neuroprotection. Exp. Neurol. 218, 347-352.
33. Mattson, M. P., and, Kroemer, G., (2003) Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med. 9, 196-205.
34. Fulda, S., Galluzzi, L., and, Kroemer, G., (2010) Targeting mitochondria for cancer therapy. Fundam. Clin. Pharmacol. 22, 335-353.
35. Biasutto, L., Dong, L. F., Zoratti, M., and, Neuzil, J., (2010) Mitochondrially targeted anti-cancer agents. Mitochondrion 10, 670-681.
36. Dias, N., and, Bailly, C., (2005) Drugs targeting mitochondrial functions to control tumor cell growth. Biochem. Pharmacol. 70, 1-12.
37. Pathania, D., Millard, M., and, Neamati, N., (2009) Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Deliv. Rev. 61, 1250-1275.
38. Ralph, S. J., and, Neuzil, J., (2009) Mitochondria as targets for cancer therapy. Mol. Nutr. Food Res. 53, 9-28.
39. Neuzil, J., Dong, L. F., Rohlena, J., Truksa, J., and, Ralph, S. J., (2012) Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion 28. doi: 10.1016/j.mito.2012.07.112.
40. Morin, D., Hauet, T., Spedding, M., and, Tillement, J., (2001) Mitochondria as target for antiischemic drugs. Adv. Drug Deliv. Rev. 49, 151-174.
41. Walters, A. M., Porter, G. A. Jr., Brookes, P. S., (2012) Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ. Res. 111, 1222-1236.
42. Garlid, K. D., Dos Santos, P., Xie, Z. J., Costa, A. D., Paucek, P., (2003) Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim. Biophys. Acta. 1606, 1-21.
43. Nihei, C., Fukai, Y., and, Kita, K., (2002) Trypanosome alternative oxidase as a target of chemotherapy. Biochim. Biophys. Acta. 1587, 234-239.
44. Sakai, C., Tomitsuka, E., Esumi, H., Harada, S., and, Kita, K., (2012) Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. Biochim. Biophys. Acta. 1820, 643-651.
45. Vaidya, A. B, and, Mather, M. W., (2009) Mitochondrial evolution and functions in malaria parasites. Annu. Rev. Microbiol. 63, 249-267.
46. Mather, M. W., Henry, K. W., and, Vaidya, A. B., (2007) Mitochondrial drug targets in apicomplexan parasites. Curr. Drug. Targets 8, 49-60.
47. Kita, K., Hirawake, H., Miyadera, H., Amino, H., and, Takeo, S., (2002) Role of complex II in anaerobic respiration of the parasite mitochondria from Ascaris suum and Plasmodium falciparum. Biochim. Biophys. Acta. 1553, 123-139.
48. Rolo, A. P., Teodoro, J. S., and, Palmeira C. M., (2012) Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 52, 59-69.
49. Liu, J., Shen, W., Zhao, B., Wang, Y., Wertz, K., et al. (2009) Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients. Adv. Drug Deliv. Rev. 61, 1343-1352.
50. Armstrong, J. S., (2007) Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. 151, 1154-1165.
51. Begriche, K., Igoudjil, A., Pessayre, D., and, Fromenty, B., (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6, 1-28.
52. Boelsterli, U. A., and, Lim, P. L., (2007) Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220, 92-107.
53. Labbe, G., Pessayre, D., and, Fromenty, B., (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam. Clin. Pharmacol. 22, 335-353.
54. Matsui, H., Shimokawa, O., Kaneko, T., Nagano, Y., Rai, K., et al. (2011) The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. J. Clin. Biochem. Nutr. 48, 107-111.
55. Szewczyk, A., Kajma, A., Malinska, D., Wrzosek, A., Bednarczyk, P., et al. (2010) Pharmacology of mitochondrial potassium channels: dark side of the field. FEBS Lett. 584, 2063-2069.
56. Lewis, W., Day, B. J., and, Copeland, W. C., (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2, 812-822.
57. Heller, A., Brockhoff, G., and, Goepferich, A., (2012) Targeting drugs to mitochondria. Eur. J. Pharm. Biopharm. 8, 21-18.
58. Yamada, Y., and, Harashima, H., (2008) Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv. Drug Deliv. Rev. 60, 1439-1462.
59. Yamada, Y., Akita, H., Kogure, K., Kamiya, H., and, Harashima, H., (2007) Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7, 63-71.
60. Wang, F., Ogasawara, M. A., and, Huang, P., (2010) Small mitochondria-targeting molecules as anti-cancer agents. Mol. Aspects Med. 31, 75-92.
61. Don, A. S., and, Hogg, P. J., (2004) Mitochondria as cancer drug targets. Trends Mol. Med. 10, 372-378.
62. Zhang, E., Zhang, C., Su, Y., Cheng, T., and, Shi, C., (2011) Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov. Today. 16, 140-146.
63. Nouette-Gaulain, K., Jose, C., Capdevila, X., and, Rossignol, R., (2011) From analgesia to myopathy: when local anesthetics impair the mitochondrion. Int. J. Biochem. Cell Biol. 43, 14-19.
64. Miyadera, H., Shiomi, K., Ui, H., Yamaguchi, Y., Masuma, R., et al. (2003) Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). Proc. Natl. Acad Sci. U S A. 100, 473-477.
65. Rial, E., Rodríguez-Sánchez, L., Gallardo-Vara, E., Zaragoza, P., Moyano, E., González-Barroso, M. M., (2010) Lipotoxicity, fatty acid uncoupling and mitochondrial carrier function. Biochim. Biophys. Acta. 1797, 800-806.
66. Russmann, S., Kullak-Ublick, G. A., Grattagliano, I., (2009) Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 16, 3041-3053.
67. Pacheu-Grau, D., Gõmez-Durán, A., Lõpez-Pérez, M. J., Montoya, J., and, Ruiz-Pesini, E., (2010) Mitochondrial pharmacogenomics: barcode for antibiotic therapy. Drug Discov. Today 15, 33-39.